objectives standard therapies for antibioticassociated diarrhea aad and clostridium difficileassociated diarrhea cdad have limited efficacyprobiotic prophylaxis is a promising alternative for reduction of aad and cdad incidencemethods in this singlecenter randomized doubleblind placebocontrolled doseranging study we randomized 255 adult inpatients to one of three groups two probiotic capsules per day pro2 n86 one probiotic capsule and one placebo capsule per day pro1 n85 or two placebo capsules per day n84each probiotic capsule contained 50 billion cfuof live organisms lactobacillus acidophilus cl1285 lactobacillus casei lbc80r biok cl1285probiotic prophylaxis began within 36 h of initial antibiotic administration continued for 5 days after the last antibiotic dose and patients were followed for an additional 21 daysresults pro2 155 had a lower aad incidence vs pro1 282each probiotic group had a lower aad incidence vs placebo 441in patients who acquired aad pro2 28 days and pro1 41 days had shorter symptom duration vs placebo 64 dayssimilarly pro2 12 had a lower cdad incidence vs pro1 94each treatment group had a lower cdad incidence vs placebo 238gastrointestinal symptoms were less common in the treatment groups vs placebo and in pro2 vs pro1conclusions the proprietary probiotic blend used in this study was well tolerated and effective for reducing risk of aad and in particular cdad in hospitalized patients on antibioticsa doseranging effect was shown with 100 billion cfu yielding superior outcomes and fewer gastrointestinal events compared to 50 billion cfuclinicaltrialsgov number nct00958308